Benzamides and related inhibitors of factor Xa

Details Benzamides and related inhibitors of factor Xa Benzamides and related inhibitors of factor Xa

2006-05-26

2008-03-11

Davis, Zinna N. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S252130, C514S318000, C514S341000, C514S352000, C514S617000, C544S124000, C544S360000, C546S193000, C546S272400, C546S309000, C564S156000

Reexamination Certificate

active

07342013

ABSTRACT:
Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.

REFERENCES:
patent: 2095619 (1937-10-01), Stoesser
patent: 4514416 (1985-04-01), Fujii et al.
patent: 4588587 (1986-05-01), Gasic
patent: 4912001 (1990-03-01), Kouno et al.
patent: 4971957 (1990-11-01), Tsutsumi et al.
patent: 5569768 (1996-10-01), Boyd et al.
patent: 5576343 (1996-11-01), Nagahara et al.
patent: 5872115 (1999-02-01), Binet et al.
patent: 6140351 (2000-10-01), Arnaiz et al.
patent: 6376515 (2002-04-01), Zhu et al.
patent: 6632815 (2003-10-01), Zhu et al.
patent: 6686368 (2004-02-01), Zhu et al.
patent: 6720317 (2004-04-01), Zhu et al.
patent: 6835739 (2004-12-01), Zhu et al.
patent: 6844367 (2005-01-01), Zhu et al.
patent: 2003/0069250 (2003-04-01), Zhu
patent: 520657 (1972-03-01), None
patent: 077534 (1983-04-01), None
patent: 540 051 (1993-05-01), None
patent: 0 798 295 (1997-10-01), None
patent: 0 937 711 (1999-08-01), None
patent: 2220206 (1990-01-01), None
patent: 418675 (1992-07-01), None
patent: 59-181257 (1994-10-01), None
patent: 11302177 (1999-11-01), None
patent: WO 94/13693 (1994-06-01), None
patent: WO 96/28427 (1996-09-01), None
patent: WO 97/21437 (1997-06-01), None
patent: WO 97/29067 (1997-08-01), None
patent: WO 98/06694 (1998-02-01), None
patent: WO 98/09630 (1998-03-01), None
patent: WO 98/28269 (1998-07-01), None
patent: WO 98/28282 (1998-07-01), None
patent: WO 98/06694 (1998-12-01), None
patent: WO 98/57934 (1998-12-01), None
patent: WO 99/00121 (1999-01-01), None
patent: WO 99/00126 (1999-01-01), None
patent: WO 99/00127 (1999-01-01), None
patent: WO 99/00128 (1999-01-01), None
patent: WO 99/10316 (1999-03-01), None
patent: WO 99/32477 (1999-07-01), None
patent: WO 99/42439 (1999-08-01), None
patent: WO 00/34237 (2000-06-01), None
patent: WO 00/34238 (2000-06-01), None
patent: WO 00/34258 (2000-06-01), None
patent: WO 00/34260 (2000-06-01), None
patent: WO 00/34261 (2000-06-01), None
patent: WO 00/34268 (2000-06-01), None
patent: WO 00/34269 (2000-06-01), None
patent: WO 00/39118 (2000-07-01), None
John D. Young, et al., “Interannular Interactions in Para-Substituted Diphenylmethane Anion Radicals”,J. Am. Chem. Soc., 94:25, pp. 8790-8794, Dec. 1972.
Hitomi Suzuki, et al., “ Selective Reduction with Lithium Aluminum Hydride/Diphosphorus Tetraiodide. A Mild Conversion of Aromatic Ketones to Parent Hydrocarbons”,Chemistry Letters, pp. 909-910, 1983.
St. Goldschmidt and P. Modderman, “Biphenyl Derivatives II Basic 4-Biphenyl Compounds”,Recueil, 69, pp. 1109-1117, 1950.
W.F. Cockburn, et al., “Molecular Rearrangement of Tertiary Amines. Part I,”J. Chem. Soc. No. 8, pp. 3340-3346 1960.
Hamilton, A., “Intra-and Intermolecular Hydrogen Bonding Control of Supermolecular Structure”NATO ASI Ser. C.(Computation Approaches in Supramolecular Chemistry), vol. 426, pp. 101-108, 1994.
El-Nagy, S.,Asian J. Chem. 2(4):368-78, 1990.
Kulkarni,J. Indian Chem. Soc. 61(8):720-721, 1984.
Hey, D.J. Chem. Soc. 16, 1513-18, 1967.
El-Zanfally,S. Egypt. J. Pharm. Sci. vol. 17(1), 29-34, 1976.
Bing-Yan Zhu, et al.,Annual Reports in Medicinal Chemistry, 35, pp. 83-102, 2000.
Michael R. Wiley, et al., Structure-Based Design of Potent, Amidine-Derived Inhibitors of Factor Xa: Evaluation of Selectively, Anticoagulant Activity, and Antithrombotic Activity,J. Med. Chem., vol. 43, pp. 883-899, 2000.
Ying K. Iee, et al., “N2-Aroylanthranilamide Inhibitors of Human Factor Xa”,J. Med. Chem., vol. 43, pp. 873-882, 2000.
David K. Herron, et al., “1-2-Dibenzamidobenze Inhibitors of Human Factor XA”,J. Med. Chem., vol. 43, pp. 859-872, 2000.
W. E. Bachmann, et al., Reduction by Magnesium +Magnesium Halide, XIII. The reaction Between Epoxy Ketones and Grignard Reagents,Journal of the American Chemical Society, vol. 56, No. 7, pp. 1559-1560, 1934.
Takashi Keumi et al., “2-(Trifluoromethylsulfonyloxy)pyridine as a Reagent for the Ketone Synthesis from Carboxylic Acids and Aromatic Hydrocarbons”,Bull. Chem. Soc. Japan., vol. 61, pp. 455-459, 1988.
“Dictionary of Organic Compounds, 5thEd., vol. 5” Chapman and Hall, New York, NY, US, compounds T-00160, T-00161, T-00162, p. 5119, 1982.
Herbert J. Sipe, Jr., et al., “An Improved Synthesis of Aryl Sulfones”,Synthesis, No. 3, pp. 283-284 1984.
Richard Kuhn et al, “Addition von Maleinsaure-anhydrid an Polyene (Uber konjugierte Doppelbindugen, XIV”Berichte Der Deutschen Chemischen Gesellschaft, vol. 63, pp. 2662-2679, 1930.
Turple,Am. J. Health Syst. Pharm., 60.(22 Suppl. 7), S20-4, Nov. 15, 2003.
Gresele et al. “Novel approaches to the treatment of thrombosis.”Trends in Pharmacological Sciences. 23(1), 25-32, Jan. 2002.
Tan, et al., “Factor X Inhibitors.”Expert Opin. Investig. Drugs, 12(5), 799-804, 2003.
Berge, S.M., et al. “Pharmaceutical Salts”J. Pharmac. Sci. 66:1-19, 1997.
Cheng, Y., et al., “Relationship between the Inhibition Constant (KI) and the Concentration of Inhibitor which Causes 50 Percent Inhibition (I50) of an Enzymatic Reaction”Biochem. Pharmacol. 22(23):3099-3108, 1973.
Claeson, G. “Synthetic peptides and peptidomimetics as substrates and inhibitors of thrombin and other proteases in the blood coagulation system”,Blood Coag. FIBRINOL. 5:411-436, 1994.
Elodi, et al. “Optimization of Conditions for the Catalytic Effect of the Factor IXa-factor VIII complex: probable role of the complex in the amplification of blood coagulation”Thromb. Res. 15:617-629, 1979.
Finlayson, K. et al., “[3H]dofetilide binding to HERG transfected membranes: A Potential High Throughout Preclinical Screen”European J. Pharmacol. 430:147, 2001.
Hauptmann, J. et al., “Comparison of the Anticoagulant and Antithrombolic Effects of Synthetic Thrombin and Factor Xa Inhibitors”,Thromb. Haemost. 63:220-223, 1990.
Haverkamp, W. et al. “The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology”Cardiovasc. Res. 47:219-33, 2000.
Hitomi, Y., et al. “Inhibitory Effect of New Synthetic Protease Inhibitor (FUT-175) on the Coagulation System”Heamostasis15:164-168 (1985).
Kam, C. et al., “Mechanism Based Isocoumarin Inhibitors for Trypsin and Blood Coagulation Serine Protease: New Anticoagulants”Biochemistry27:2547-2557 (1988).
Kuzmic, P. et al., “High-throughput Screening of Enzyme Inhibitors: Automatic Determination of Tight-Binding Inhibition Constants”Anal. Biochem281:62-67 (2000).
Netzer, R. et al., “Screening Lead Compounds for QT Interval Prolongation”Drug Discovery Today. 6:78-84 (2001).
Nutt, E. et al., “The Amino Acid Sequence of Antistasin, a Potent Inhibitor of Factor XA Reveals a Repeated Internal Structure”J. Biol. Chem. 263:10162-10167 (1988).
Pearlstein, R. Et al., “Characterization of HERG Potassium Channel Inhibition Using CoMSiA 3D QSAR and Homology Modeling Approaches”Bioorg. Med. Chem. Lett. 13:1829-35 (2003).
Redfern, W. et al., “Relationships between preclinical Cardiac Electrophysiology, Clinical QT Interval Prolongation and Torsade de Pointes for a Broad Range of Drugs: Evidence for a Provisional Safety Margin in Drug Development”Cardiovasc. Res. 58:32-45 (2003).
Sturzebecher, J. et al., “Synthetic Inhibitors of Bovine Factor Xa and Thrombin. Comparison of Their Anticoagulant Efficiency”,Thromb. Res. 54:245-252 (1989).
Tidwell, R. et al., “Strategies for Anticoagulation with Synthetic Protease Inhibitors. Xa Inhibitors Versus Thrombin Inhibitors”Thromb. Res. 19:339-

Affiliated with

Also associated with

Rating

Benzamides and related inhibitors of factor Xa does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Benzamides and related inhibitors of factor Xa, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzamides and related inhibitors of factor Xa will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3964447